The effect of antacid and aspirin on the bioavailability of isofezolac in man.
Bioavailability of isofezolac, a new non-steroid anti-inflammatory drug, with or without antacid and aspirin coadministration was investigated in 6 healthy volunteer. Each subject received, in random order, isofezolac (50 mg) alone or associated with aspirin (1 g) or phosphalugel (11 g aluminum phosphate). Isofezolac plasma concentrations were salicylic acid by spectrofluorimetric method. Plasma protein binding of drugs was studied by dialysis equilibrium method. During the absorption phase isofezolac plasma levels were slightly decreased in association with isofezolac-aspirin, but bioavailability of isofezolac was not modified. Time to peak of isofezolac was comparable in the three treatments, as was the case with plasma half-lives. Aluminum phosphate did not modify isofezolac availability. Plasma protein binding of isofezolac was very high (99%) and did not influence salicylic acid binding.
D000328:Adult; D017607:Aluminum Compounds; D000863:Antacids / Q000494:pharmacology*; D000893:Anti-Inflammatory Agents / Q000378:metabolism*; D001241:Aspirin / Q000494:pharmacology*; D001682:Biological Availability / Q000187:drug effects; D001798:Blood Proteins / Q000378:metabolism; D004347:Drug Interactions; D005260:Female; D006801:Humans; D007700:Kinetics; D010710:Phosphates / Q000494:pharmacology; D011485:Protein Binding / Q000187:drug effects; D011720:Pyrazoles / Q000097:blood / Q000378:metabolism*; D012459:Salicylates / Q000097:blood; D020156:Salicylic Acid
D017607:Aluminum Compounds; D000863:Antacids; D000893:Anti-Inflammatory Agents; D001798:Blood Proteins; D010710:Phosphates; D011720:Pyrazoles; D012459:Salicylates; C020696:isofezolac; C012714:aluminum phosphate; D020156:Salicylic Acid; D001241:Aspirin